Expression of P-glycoprotein in hepatocellular carcinoma: A potential marker of prognosis

Journal of Clinical Pathology

Volumn 49, Issue 6, 1996, Pages 470-473

  Soini, Y ^a   Virkajarvi N ^a   Raunio, H ^a   Paakko P ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Hepatocellular carcinoma; Liver; MDR; p53; PCNA

Indexed keywords

CYCLINE; MITOMYCIN C; PROTEIN P53; TUMOR MARKER;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 0029882948     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.6.470     Document Type: Article

References (17)

1. Dietel M. What's new in cytostatic drug resistance and pathology. Pathol Res Pract 1991;187:892-905.
2. Gottesman MM. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal foundation Award lecture. Cancer Res 1993;53:747-54.
3. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues, J Histochem Cytochem 1990;38:1277-87.
4. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991;83:111-16.
5. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinoma: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994; 86:1539-45.
6. Kramer R, Weber TK, Morse B, Arceci R, Staniunas R, Steele G, Summerhayes IC. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 1993;67:959-68.
7. Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994;74:2908-17.
8. Duensing S, Dallmann I, Grosse J, Buer J, Lopez Hanninen E, Deckert M, et al. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 1994;51:309-13.
9. Itsubo M, Ishikawa T, Toda G, Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma, Cancer 1994;73:298-303.
10. Silverman JA, Thorgeirsson SS. Regulation and function of the multidrug resistance genes in liver. In: Boyer JD, Ockner RK, eds. Progress in liver sisease. Vol XII. Philadelphia: WB Saunders, 1995:101-23.
11. Gibson JB, Sobin LH. Histological typing of tumours of the liver, biliary tract and pancreas. International histological classification of tumours. No 20. Geneva: World Health Organization, 1978.
12. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer 1954;7:462-503.
13. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G. TNM Atlas. Illustrated guide to the TNM/pTNM classification of malignant tumours. 3rd edn. Berlin: Springer Verlag, 1992.
14. Soini Y, Pääkkö P, Nuorva K, Kamel D, Lane D, Vähäkangas K. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch A Pathol Anat Histopathol 1992;421:223-8.
15. Park JG, Lee SK, Hong IG, Kim HS, Choe KJ, Kim WH, et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994;86:700-5.
16. Chin K-V, Ueda K, Pastan I, Gottesmann MM. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992;255:459-62.
17. De Angelis P, Stokke T, Smedshammer L, Lothe RA, Lehne G, Chen Y, Clausen OPF. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995;72:307-11.